Published in J Med Case Rep on June 25, 2009
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody. J Autoimmun (2007) 0.94
Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. Hematol J (2004) 0.89
A rare presentation of visceral leishmaniasis without fever or splenomegaly in an elderly person. Eur J Intern Med (2007) 0.89
The presence of rheumatoid factor in sera from anti-HCV positive blood donors interferes with the detection of HCV-specific IgM. Trent HCV Study Group. J Hepatol (1996) 0.88
Acute hepatitis as a presenting manifestation of kala azar. Pediatr Infect Dis J (1991) 0.87
Visceral leishmaniasis masquerading as chronic liver disease. J Assoc Physicians India (2006) 0.84
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol (2012) 6.36
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology (2010) 5.24
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology (2008) 2.28
Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci (2002) 2.10
Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance. Liver Int (2013) 2.07
PAP/HIP protein is an obesogenic factor. J Cell Physiol (2014) 1.98
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity (2008) 1.95
Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med (2010) 1.88
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med (2013) 1.64
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood (2010) 1.60
Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology (2014) 1.58
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res (2003) 1.55
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood (2012) 1.52
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem (2003) 1.50
Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood (2009) 1.48
Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. Cancer Discov (2013) 1.47
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum (2009) 1.41
Hepatocellular carcinoma: comparison of two different periods at the same center. Eur J Intern Med (2010) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood (2011) 1.40
Celiac disease in the developing countries: a new and challenging public health problem. World J Gastroenterol (2007) 1.40
Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood (2006) 1.38
CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res (2009) 1.34
Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol (2006) 1.31
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood (2010) 1.27
Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clin Chem (2002) 1.24
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res (2007) 1.21
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One (2010) 1.16
An automated image analysis methodology for classifying megakaryocytes in chronic myeloproliferative disorders. Med Image Anal (2008) 1.10
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann N Y Acad Sci (2004) 1.09
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol (2011) 1.08
Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol (2006) 1.07
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis. Cell Stress Chaperones (2013) 1.05
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol (2005) 1.04
A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. Eur J Immunol (2010) 1.02
Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle (2012) 1.01
Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome. Clin Gastroenterol Hepatol (2011) 1.00
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol (2014) 1.00
The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica (2013) 1.00
Serum low density lipoprotein subclasses in asthma. Respir Med (2013) 1.00
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol (2005) 1.00
Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol (2008) 0.99
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci (2004) 0.99
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med (2004) 0.99
Pathobiology of hodgkin lymphoma. Adv Hematol (2010) 0.98
An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol (2010) 0.98
Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer (2004) 0.97
Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica (2004) 0.97
Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol Immunol (2008) 0.97
Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol (2013) 0.96
Autoimmune enteropathy and colitis in an adult patient. Dig Dis Sci (2003) 0.96
Use of intrapleural bortezomib in myelomatous pleural effusion. Br J Haematol (2007) 0.95
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle (2010) 0.95
MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res (2011) 0.95
The aryl hydrocarbon receptor modulates acute and late mast cell responses. J Immunol (2012) 0.95
Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res (2011) 0.95
Emerging Raf inhibitors. Expert Opin Emerg Drugs (2009) 0.94
SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. Am J Pathol (2011) 0.94
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients (2013) 0.94
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging (2009) 0.94
Solitary necrotic nodule of the liver: different pathological findings express a different histogenesis. Case Rep Gastroenterol (2008) 0.93
Bone marrow biopsy in Hodgkin's lymphoma. Eur J Haematol (2004) 0.93
Exploring a regulatory role for mast cells: 'MCregs'? Trends Immunol (2010) 0.93
How I diagnose and treat splenic lymphomas. Blood (2010) 0.92
Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA-secreting plasma cells. Blood (2010) 0.92
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther (2007) 0.92
Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. Eur J Haematol (2006) 0.91
C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. Blood (2009) 0.91
Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design. Eur J Pharm Biopharm (2007) 0.91
Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res (2010) 0.91
Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. OMICS (2011) 0.91
Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells. J Steroid Biochem Mol Biol (2009) 0.90
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study . Ann N Y Acad Sci (2009) 0.89
C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci U S A (2014) 0.89
Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. Hematol J (2004) 0.89
IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS (2011) 0.89
The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett (2012) 0.89
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood (2011) 0.89